Indivior PLC (NASDAQ:INDV) is among the best performing pharma stocks in 2025, with a full-year 2026 financial guidance predicting total net revenue in the range of $1.125 billion to $1.195 billion and SUBLOCADE net revenue in the $905 million to $945 million range. The company has completed Phase I of its Indivior Action Agenda and is poised for growth in Phase II in 2026, expecting to increase SUBLOCADE net revenue by 11% and adjusted EBITDA by 35%. Recent highlights include inclusion in the S&P SmallCap 600® index and a change in domicile from the U.K. to the U.S. Indivior PLC develops buprenorphine-based prescription drugs to treat opioid dependence.

Read more at Yahoo Finance: Indivior PLC (INDV) Announces Full-Year 2026 Financial Guidance